Disc Medicine price target lowered to $125 from $153 at Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska lowered the firm’s price target on Disc Medicine (IRON) to $125 from $153 and keeps an Overweight rating on the shares. Disc Medicine received a Complete Response Letter for bitopertin in treating EPP and XLP, with the FDA requesting additional trial evidence to link the surrogate endpoint to clinical benefit, the analyst tells investors in a research note. Despite this, confidence remains high in the ongoing Phase 3 APOLLO trial, viewed as a strong buying opportunity ahead of the expected 4Q26 readout, Cantor says.